According to WHO, cancer is the second leading cause of death worldwide, a number that continues to grow, exerting enormous physical, emotional and financial pressure on individuals, families, communities and health systems. In addition, the economic impact of cancer is significant and growing, with an estimated US$1.16 trillion in global expenditures in 2010 alone. There is an increased survival rate in countries with robust health systems due to access to early detection, quality treatments, and survival care. However, there are still many countries with health systems that cannot provide them in helpful time.
WHO also states that “30% to 50% of cancer deaths could be avoided if the main risk factors were modified or avoided through prevention strategies and early detection and treatment. Prevention proves to be the most cost-effective long-term strategy for disease control”.
And it’s IARC, the WHO’s International Agency for Research on Cancer, whose mission is to promote international collaboration in cancer research and increase political commitment in identifying priority strategies. Among the various goals is to improve breast cancer control, reduce the death rate through the Global Breast Cancer Initiative, and promote the rapid and effective transfer of best intervention practices.
About the prevention and early diagnosis of breast cancer remember here one of the latest achievements of our community: the recent partnership between GLOOMA and Cuf Descobertas. This partnership will allow GLOOMA to carry out the clinical studies necessary to develop the SenseGlove algorithm, validate it with the medical community and achieve the required certifications to be marketed in the European Economic Area.
SenseGlove is a device for easy and domestic use. You just put on your glove, perform a palpation self-examination (3 min.), and the results are interpreted and communicated by the mobile application, which, if necessary, recommends going to the doctor. In addition, it reminds you of the need to carry out a self-examination via email or mobile phone notifications and provides a detailed follow-up of breast health. The main goal is to take women to the doctor as soon as possible, not replacing complementary diagnostic tests or routine consultations.
Glooma expects to have SenseGlove ready by the end of 2022 with 100 units available and the following ones only in 2023. Booking them on the website is now possible, with the first pre-bookings getting a 25% discount on the current value of €59.99.